Study: Novo Nordisk NN9489-8035 “AMBITION 3”

Are you living with type 2 diabetes and obesity and are taking metformin or an SGLT-2 inhibitor (such as Jardiance, Farxiga, or Invokana), or both?

If so, you may be eligible to participate in a clinical research study assessing an investigational GLP-1 medicine called zenagamtide.

ABOUT THE STUDY

This is a Phase 3 study assessing how zenagamtide affects blood sugar levels and body weight.

Who may qualify?

You may be eligible to participate if you meet all the following:

• Age 18 years or older

  Have type 2 diabetes

  Currently taking metformin, an SGLT-2 inhibitor (such as Jardiance, Farxiga, or Invokana), or both

  HbA1c between 7.5% and 10.5%

  BMI of 30 or higher (classified as obesity)

  Have not used any GLP-1-based medication — including pills or injections (such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, or Foundayo) — within the past year

  Have never had surgery for treatment of obesity

Interested in learning more?
Click below to complete a short questionnaire to see if you may be eligible.
(insert JotForm link)